Accelerating drug discovery through tight integration of expert molecular design and predictive scoring.

[1]  Liang Tong,et al.  A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. , 2004, Molecular cell.

[2]  A. Cavalli,et al.  Role of Molecular Dynamics and Related Methods in Drug Discovery. , 2016, Journal of medicinal chemistry.

[3]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[4]  M. Ratner.  Gilead bets big on Nimbus' fatty liver disease drug , 2016, Nature Biotechnology.

[5]  M. Johnson,et al.  Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study , 2015, PloS one.

[6]  Liang Tong,et al.  Molecular basis for the inhibition of the carboxyltransferase domain of acetyl-coenzyme-A carboxylase by haloxyfop and diclofop. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[8]  R. McPherson,et al.  Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. , 2010, Bioorganic & medicinal chemistry letters.

[9]  Robert Abel,et al.  Leveraging Data Fusion Strategies in Multireceptor Lead Optimization MM/GBSA End-Point Methods. , 2014, Journal of chemical theory and computation.

[10]  X. Langlois,et al.  Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors. , 2015, ACS medicinal chemistry letters.

[11]  Wilfred F van Gunsteren,et al.  Practical Aspects of Free-Energy Calculations: A Review. , 2014, Journal of chemical theory and computation.

[12]  Woody Sherman,et al.  Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation , 2016, ACS omega.

[13]  L. Tong,et al.  Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186. , 2004, Structure.

[14]  Robert Abel,et al.  Sensitivity in binding free energies due to protein reorganization , 2016, bioRxiv.

[15]  S. Wakil,et al.  Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Filizola,et al.  Predicted mode of Binding of Non-Nitrogenous μ-Opioid Receptor Ligands by Metadynamics , 2016 .

[17]  Liang Tong,et al.  Acetyl‐coenzyme A carboxylases: Versatile targets for drug discovery , 2006, Journal of cellular biochemistry.

[18]  Jennifer L. Knight,et al.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.

[19]  William L. Jorgensen,et al.  Enhanced Monte Carlo Sampling through Replica Exchange with Solute Tempering , 2014, Journal of chemical theory and computation.

[20]  L. Tong,et al.  Crystal structure of the 500 kD yeast acetyl-CoA carboxylase holoenzyme dimer , 2015, Nature.

[21]  Y. Sekine,et al.  Tyk2 is a therapeutic target for psoriasis-like skin inflammation. , 2014, International immunology.

[22]  M. P. Bourbeau,et al.  Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease. , 2015, Journal of medicinal chemistry.

[23]  D. James,et al.  Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. , 2010, Cell metabolism.

[24]  Arthur J. Olson,et al.  Virtual screening of integrase inhibitors by large scale binding free energy calculations: the SAMPL4 challenge , 2014, Journal of Computer-Aided Molecular Design.

[25]  Julien Michel,et al.  Blinded predictions of binding modes and energies of HSP90-α ligands for the 2015 D3R grand challenge. , 2016, Bioorganic & medicinal chemistry.

[26]  B. Berne,et al.  Replica exchange with solute scaling: a more efficient version of replica exchange with solute tempering (REST2). , 2011, The journal of physical chemistry. B.

[27]  William L Jorgensen,et al.  Computer-aided discovery of anti-HIV agents. , 2016, Bioorganic & medicinal chemistry.

[28]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[29]  R. Zwanzig.  High‐Temperature Equation of State by a Perturbation Method. I. Nonpolar Gases , 1954 .

[30]  Joseph A Morrone,et al.  Advances in free-energy-based simulations of protein folding and ligand binding. , 2016, Current opinion in structural biology.

[31]  Hyun-soo Cho,et al.  Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK. , 2010, Biochemical and biophysical research communications.

[32]  D. Stiller,et al.  Inhibition of acetyl-CoA carboxylase 2 enhances skeletal muscle fatty acid oxidation and improves whole-body glucose homeostasis in db/db mice , 2012, Diabetologia.

[33]  B. Lowell,et al.  Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake , 2010, Proceedings of the National Academy of Sciences.

[34]  Xinyi Huang,et al.  Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats , 2016, Proceedings of the National Academy of Sciences.

[35]  G. Shulman,et al.  Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. , 2006, The Journal of clinical investigation.

[36]  Laura Pérez-Benito,et al.  Application of Free Energy Perturbation for the Design of BACE1 Inhibitors , 2016, J. Chem. Inf. Model..

[37]  Joshua C. Denny,et al.  TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits , 2015, PloS one.

[38]  Robert Abel,et al.  Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.

[39]  D. Shaw,et al.  Assessment of the utility of contact‐based restraints in accelerating the prediction of protein structure using molecular dynamics simulations , 2015, Protein science : a publication of the Protein Society.

[40]  Pratyush Tiwary,et al.  Prediction of Protein-Ligand Binding Poses via a Combination of Induced Fit Docking and Metadynamics Simulations. , 2016, Journal of chemical theory and computation.

[41]  H. Harwood,et al.  The adipocyte as an endocrine organ in the regulation of metabolic homeostasis , 2012, Neuropharmacology.

[42]  Liang Tong,et al.  Crystal Structure of the Carboxyltransferase Domain of Acetyl-Coenzyme A Carboxylase , 2003, Science.

[43]  J. Yates,et al.  TRB3 Links the E3 Ubiquitin Ligase COP1 to Lipid Metabolism , 2006, Science.

[44]  Michael Bergdorf,et al.  Desmond/GPU Performance as of November 2014 , 2014 .

[45]  H. J. Harwood,et al.  Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. , 2005, Expert opinion on therapeutic targets.

[46]  Atli Thorarensen,et al.  Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free‐Energy Perturbation (FEP) , 2016, ChemMedChem.

[47]  Edward D Harder,et al.  How To Deal with Multiple Binding Poses in Alchemical Relative Protein–Ligand Binding Free Energy Calculations , 2015, Journal of chemical theory and computation.

[48]  B. Berne,et al.  Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. , 2008, Journal of the American Chemical Society.

[49]  D. Hargrove,et al.  Isozyme-nonselective N-Substituted Bipiperidylcarboxamide Acetyl-CoA Carboxylase Inhibitors Reduce Tissue Malonyl-CoA Concentrations, Inhibit Fatty Acid Synthesis, and Increase Fatty Acid Oxidation in Cultured Cells and in Experimental Animals* , 2003, Journal of Biological Chemistry.

[50]  M. Dowty,et al.  Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[51]  Matthew P. Repasky,et al.  WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand-Receptor Docking. , 2016, Journal of medicinal chemistry.

[52]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[53]  L. Tong,et al.  Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery , 2005, Cellular and Molecular Life Sciences CMLS.

[54]  J. Dyck,et al.  Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin–sensitizing effects of metformin , 2013, Nature Medicine.

[55]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.

[56]  E. Ravussin,et al.  Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes , 2014, Journal of medicinal chemistry.

[57]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[58]  Martin M. Matzuk,et al.  Continuous Fatty Acid Oxidation and Reduced Fat Storage in Mice Lacking Acetyl-CoA Carboxylase 2 , 2001, Science.